Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| KD | Kyndryl | $10.60 | -$12.89 | -54.87% | 3.9K | $2.4B | $10.10$44.20 |
| PLYX | Polaryx Therapeutics | $5.93 | -$2.98 | -33.45% | 23.2K | $281M | $2.51$48.91 |
| VHUB | VenHub Global | $3.49 | -$1.34 | -27.74% | 12.4K | $261M | $3.40$40.30 |
| PFSA | Profusa | $3.16 | -$1.21 | -27.73% | 35.2K | $273M | $2.90$957.00 |
| PGY | Pagaya Technologies | $14.16 | -$4.48 | -24.03% | 9.9K | $1.1B | $8.50$44.99 |
| MNDY | Monday.com | $77.28 | -$20.72 | -21.14% | 2.8K | $3.9B | $73.01$334.90 |
| DBGI | Digital Brands Group | $5.19 | -$1.37 | -20.88% | 6.5K | $42M | $1.06$18.00 |
| CGTL | Creative Global Technology | $3.66 | -$0.93 | -20.26% | 5.5K | $110M | $0.41$6.52 |
| RDIB | Reading International | $11.01 | -$2.45 | -18.20% | 1.7K | $250M | $5.81$17.40 |
| MPAA | Motorcar Parts Of America | $10.84 | -$2.30 | -17.50% | 152 | $212M | $6.26$18.12 |
| FLYE | Fly-E Group | $2.86 | -$0.60 | -17.34% | 8.2K | $4.7M | $2.50$161.80 |
| CLF | Cleveland-Cliffs | $12.31 | -$2.42 | -16.43% | 102.2K | $7.0B | $5.63$16.70 |
| HIMS | Hims & Hers Health | $19.33 | -$3.69 | -16.03% | 1.3M | $4.4B | $16.35$72.98 |
| NXTT | Next Technology | $3.14 | -$0.58 | -15.59% | 1.9K | $13M | $3.05$960.00 |
| MAXN | Maxeon Solar Technologies | $3.29 | -$0.60 | -15.42% | 15.2K | $56M | $2.46$6.02 |
| ASST | Strive Asset Management, Llc | $10.15 | -$1.77 | -14.86% | 62.7K | $633M | $7.73$268.40 |
| ZBAI | Atif | $5.98 | -$1.00 | -14.33% | 28 | $62M | $4.83$22.50 |
| WAT | Waters | $327.78 | -$53.51 | -14.03% | 146 | $20B | $275.05$414.15 |
Related Articles
Featured Article
Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?
Bram Berkowitz|Feb 9, 2026
Hims & Hers could face difficulty in the future in selling copycat GLP-1 drugs.
Hims & Hers Takes On Novo Nordisk: What We Know Right Now
Travis Hoium|Feb 5, 2026
Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering
Travis Hoium|Feb 4, 2026
Hims & Hers is moving beyond prescriptions to preventative testing.
Stocks to Love in 2026
Motley Fool Staff|Jan 11, 2026
Are you looking for investment opportunities in 2026?
Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip?
Parkev Tatevosian, CFA|Nov 26, 2025
The healthcare industry is ripe for disruption.
Monday.com Stock Is Crashing. Time to Buy the Dip?
Timothy Green|Nov 10, 2025
The software company's slight guidance cut tanked the stock.
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
Geoffrey Seiler|Nov 9, 2025
The company continues to have a strong growth outlook ahead.
Hims & Hers Stock Jumps 9% After Huge Announcement
Travis Hoium|Oct 16, 2025
New products are coming to the Hers platform.
1 Growth Stock Down 30% You Don't Want to Miss On
Neil Rozenbaum|Oct 6, 2025
The recent pullback is a blessing in disguise.
Cleveland-Cliffs Stock Just Keeps Dropping. Buying Opportunity, or a Sign to Steer Clear?
Reuben Gregg Brewer|Oct 1, 2025
Cleveland-Cliffs is losing money as the steel industry deals with a downturn, which is exactly why you might want to buy it.
